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Neutralizing antibody patterns in sera of persons infected with human immunodeficiency virus 
type 1 (HIV-1) groups M and O to their homologous and heterologous primary isolates were 
determined in a peripheral blood mononuclear cell-based neutralization assay and correlated with 
their ability to bind to V3 loop synthetic peptides. Most HIV-1 group M sera (9116) neutralized 
HIV-1 group O viruses, whereas fewer group O sera (3/13) only weakly neutralized HIV-1 group 
M viruses. Group M sera neutralizing HIV-1 group O viruses neutralized other HIV-1 group M 
viruses with titers of 1:lO-1:1280. V3 loop binding capacity of sera did not reflect their neutralizing 
capacity of the homologous isolate. Despite the reduced neutralizing capacity of group O-infected 
patients' sera to group M viruses, some group M-infected patients' sera neutralized both HIV-1 
group M and O isolates, suggesting that they share some conserved neutralizing epitopes. 
Nucleic acid sequence analysis of the envelope gene of hu- 
man immunodeficiency virus type 1 (HIV-I) isolates has thus 
far distinguished at least 8 subtypes, A-H [I-31, which to- 
gether are referred to as HIV-I group M (for major). However, 
the relevance of these genetic subtypes in terms of neutraliza- 
tion serotypes is not known. Recently, more divergent HIV-I 
strains, "temporarily classified as HIV-1 group O (for genetic 
outliers), have been described and sequence information made 
available [4-71. Even though their genomic organization is 
similar to that of HIV-I group M viruses, their envelope gene 
products show a 50% restriction homology with HIV-1 refer- 
ence strains of group M [7]. The amino acid sequence at the 
tip of the V3 loop (the principal neutralizing domain) for these 
group O viruses is quite distinct (GPMAWY for HIV-1ANT70 
and VAU [4, 71 and GPMRW for MVP5180 [6]) from those 
frequently found in EuropeadAmerican (GPGRAF) and Afri- 
can (GPGQAL) HIV-1 isolates [8, 91. 
Given the observed genetic diversity between HIV-1 group 
M and O viruses, a key question relevant to vaccine design 
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is whether this genetic diversity reflects antigenic diversit> 
Independent studies have shown that sera from HIV-I -infected 
humans can neutralize a broad spectrum of HIV-1 isolates [lo- 
121. However, these studies lacked information on the genetic 
subtypes to which the virus isolates or sera belonged. In a 
recent study, Moore et al. [13] demonstrated that some primary 
HIV-I isolates of genetic subtype B were sensitive to neutral- 
ization by some monoclonal antibodies, even though most of 
the isolates were resistant to neutralization. This neutralization 
by monoclonal antibodies may not reflect the neutralizatioli 
capacity of sera in vivo. However, in a previous study, Mascola 
et al. [14], using aperipheral blood mononuclear cell (PBMC)- 
based neutralization assay with plasma and viruses represent- 
ing 2 distinct HIV-I subtypes (B and E), demonstrated that 
HIV- 1 viral genotypes predict neutralization serotypes. If these 
observations are confirmed for other HIV-1 subtypes of group 
M and O viruses, then an effective vaccine for humans against 
HIV-1 may have to contain neutralizing epitopes representing 
distinct genetic subtypes. . 
In this study, we report on the capacity of sera of HIV-I 
group M- and group O-infected persons to neutralize their 
homologous and heterologous primary and laboratory HIV-I 
isolates in a PBMC-based neutralization assay. The HIV-I iso- 
lates and sera from group M (subtypes A-H) and group O 
were chosen on the basis of phylogenetic classification of the 
e m  or gag gene (or both). We also examined the relationshij- 
between the presence of neutralizing antibodies in sera anci 
their ability to bind to the honiologous V3 synthetic peptide 
of the isolate. 
Materials and Methods 
Patient sera. A total of 29 sera obtained from patients from 
whom HIV-1 had been isolated were tested for the presence of 
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neutralizing antibodies. Of these, I6 were from patients infected 
with group M (subtype A-H) and 13 from patients with group 0 
viruses. Sera and viruses were collected at the same time after 
infection, except for sera V19 18 and V1498, which were collected 
4 and 3.5 years after virus isolation, respectively. Sera were given 
the same identification numbers as the corresponding isolates. The 
corresponding viruses of the group M sera classified into genetic 
subtypes A-H and clinical stages, based on the World Health 
Organization (WHO) clinical AIDS definition [15], are as follows: 
subtype A: CAI (symptomatic), CAI 8 and VI191 (asymptomatic); 
B: CA5 (asymptomatic), C122 (symptomatic); C: VI3 13 (asymp- 
tomatic); D: CI 13 and VI9 1 8 (symptomatic); E: CAI O (symptom- 
atic); F: CA4 (symptomatic), CA 16 and CA20 (asymptomatic); G: 
VI525 and VI526 (symptomatic); H: CA13 (symptomatic), VI557 
(asymptomatic). 
The group O sera were V1498, FAN, MVP6116, MVP7852, and 
MVP8 166 from asymptomatic and CA9, VI686, DUR, MAA, ESS, 
LOB, MVP7851, and MVP8161 from symptomatic persons. The 
classification into genetic subtypes is based on sequence informa- 
tion obtained from the env or gag genes [ l ,  3, 16, 171 (unpublished 
data). Sera designated by code CA or MVP, CI, and VI, respec- 
tively, were obtained from seropositive persons in Cameroon, 
Ivory Coast, and Belgium. VI sera were obtained from persons 
consulting at the Institute of Tropical Medicine in Antwerp. Speci- 
mens VI686, V1525, and VI526 were from Gabonese living in 
Gabon. Four group O sera were obtained from Cameroonians 
(FAN, ESS, MAA, LOB) living in France and 1 (DUR) from a 
French citizen. 
Fifteen HIV-I primary isolates of group M 
were classified into subtypes A-H on the basis of phylogenetic 
analysis of the etit’ (V3-V5 and beginning of gp41) or gug genes 
[l ,  3, 16, 171. Two primary HIV-1 group O isolates, CA9 and 
VI686, were genetically characterized on the basis of the pol and 
e m  (gp160) sequences [I81 (unpublished data). The HIV-~*N~~,, 
(group O) isolate has recently been completely sequenced [7]. The 
strains had been cultured only once or twice in PBMC. In addition, 
3 HIV-1 laboratory strains were used: H I V - l I I ~ ~  and H 1 v - l ~ ~  
(provided by R. Gallo, National Cancer Institute, Bethesda, MD) 
and HIV-lMAL (provided by L. Montagnier, Institut Pasteur, Paris). 
These isolates, provided as chronically infected H9 cells, were 
passaged in PBMC to eliminate the influence of any host cell- 
dependent epigenetic factors on virus neutralization [ 191. Virus 
stocks were prepared on phytohemagglutinin (PHA)-stimulated 
primary human PBMC and titrated essentially as described [IO]. 
Neutralization assay. Neutralization was done as described 
[ 101 with some modifications. Tissue culture supernatants of 
PBMC infected with virus (50 TClD50,) and 2-fold serial dilutions 
of heat-inactivated (56°C for 30 min) serum were incubated for 1 
h at 37°C in a 5% CO2 atmosphere before addition of 5 x 10‘ 3- 
day PHA-stimulated PBMC for 2 h. The cells were washed and 
incubated in RPMI 1640/interleukin-2 medium (GIBCO, Paisley, 
UK) supplemented with 10% fetal calf serum, 0.03% L-glutamine, 
(Janssen Chimica, Geel, Belgium), and antibiotics. Viral replica- 
tion was assessed after 7 days by an in-house p24 antigen-capture 
A series of experiments was done to ensure the validity of the 
neutralization assay. In each neutralization assay on PBMC, virus 
was titrated again to check the titer. If the titer differed by >3- 
fold dilutions, neutralization assays were considered invalid and 
repeated. To ensure the reproducibility of our method, 25% of sera 
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Amino acid sequences 
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CNTRKRIRIQRGPGRAFVTI 
Subtype D 
MAL CNTRRGIHFGPGQALYTTGI 
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ANT70 CDIQEMRIGPMAWY SMGIG 
Figure 1. Reactivity ofboth HIV-1 group M- and O-infected sera 
were tested on 3 HIV-I group M (MN, HXB2, and Mal) and 1 HIV- 
1 group O (ANT7O) v3-100~ synthetic peptides. 
were randomly retested. In each neutralization assay, the last wash 
fluid obtained after washing away the nonabsorbed serum-virus 
mixture was carefully monitored for the presence of residual p24 
antibody by use of a commercial HIV-1 and -2 antibody ELISA 
(Vironostika HIV Uni-Form II; Organon Teknika, Boxtel, Nether- 
lands) as described [lo]. Such a control is important since p24 
antibody could complex with the p24 antigen released in culture 
and interfere with p24 antigen detection. The ability of our in- 
house p24 antigen-capture ELISA to equally detect p24 antigen 
of both group M and O viruses was also confirmed. Neutralizing 
titers were defined as the reciprocal of the highest serum dilution 
giving a 90% reduction in absorbance in the HIV antigen assay 
compared with negative controls. HIV-1 serum neutralizing titers 
of 3 1 : 1 O were considered positive. 
Peptides and peptide ELISA. All peptides used were synthe- 
sized by Neosystem Laboratoire (Strasbourg, France). A total of 
four peptides corresponding to the gp120 V3 region of HIV-1 were 
evaluated: of  subtype B, 2 strains of North American origin (HIV- 
 lb,^ and HBX2 [HIV-llllB]), of subtype D, 1 African strain (HIV- 
IMAL), and of group O, HIV-IANnO (subtypes according to the 
classification of Myers et al. [2]). The amino acid residues of these 
peptides covered the principal neutralization domain containing 
the V3 loop of gp120 (figure 1). 
Micro-ELISA plates (Nunc, Roskilde, Denmark) were coated 
with 100 ng of peptidelwell in 200 pL of 0.05 mol/L carbonate 
buffer (pH 9.6) ovemight and stored at -20°C until use. The assay 
was done essentially as described [lo]. 
Westem blots were prepared from H l v - 1 ~ ~ ~ 7 0  
as described [20] with some minor modifications. In brief, superna- 
tant of virus grown on Molt-4 clone 8 cells in RPMI 1640 supple- 
mented with 1% nutridoma (Boehringer, Mannheim, Germany), 
0.03% glutamine, gentamicin, and 0.1% fetal calf serum was pel- 
leted by centrifugation. Virus pellets were resuspended in an elec- 
wesfern blot. 
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Table 1. Neutralizing antibodies to diverse HIV-1 isolates by sera of HN-1 group O- and group M-infected persons. 
Reciprocal of neutralizing antibody titer against HIV isolate of group 
O A B D F G 
Subtype, C, E, 8, 
serum ANT70 CA9 VI686 CA1 CAI8 VI191 MN IIIB CI22 CA5 VI313 CI13 VI205 MAL CAlO CA4 CA16 CAZO VI525 VI526 CA13 
Group O 
VI498 
CA9 
VI686 
DUR 
FAN 
MAA 
ESS 
Group M 
CA 1 
CA18 
VI191 
CAS 
CI22 
C, VI313 
D 
CI13 
VI918 
E, CAlO 
F 
CA4 
CA16 
CAZO 
VI525 
VIS26 
CA13 
VI557 
A 
B 
G 
H 
160 40 
IO 40 - -  
- 
IO 10
640 640 
320 80 
20 10 
> 1280 
160 
10 
640 80 >I280 
640 - SI280 
20 80 10 
320 160 640 320 
40 160 80 
20 80 20 
20 80 1280 
20 
20 - -  
640 160 160 40 
160 40 40 - 
20 10 
40 40 
- -  
20 
40 
- 10 
80 - 160 
- - 10 IO 
IO IO 40 20 
- -  - - -  
- 20 40 
- - - -  
S O - - -  
80 40 
20 40 
- -  40 
20 
- 160 10 640 
160 320 40 
20 10 IO 
- -  l o  
- - -  
40 40 160 80 
10 - 
IO 20 80 20 
- - 
IO 20 80 
80 - I60 
- -  
160 10 10 20 
80 IO - - 
- 
20 80 80 _ - -  
I O  lo so - - -  160 40 20 - - - - -  
160 20 20 40 80 40 
10 10 
40 
IO 
160 - 320 20 40 40 80 - 10 320 
NOTE. Empty space indicates test not done due to limited amount of serum. Sera and isolates indicated with same identity indicate same time of collection. 
Sera VI498 and VI918,'respectively, were collected from patients infected with ANT70 and VI205 isolates, respectively, 3.5 and 4 years after virus collection. 
Genetic subtypes of HIV-1 group M isolates are based on env gene. Isolate VI313 in subtype C is based on total gag gene sequence. Primary isolates with total 
gp160 sequence information include CA9, VI686, ANT70, VI191, and VI525; isolates with V3-V5 and start of gp41 sequence include CAI, CA18, CA5, CAIO, 
CA4, CA16, CA13, CI22, CI13, and VI.526; and with total gag sequence include VI313, VI205, VI191, and VI525. -, neutralizing antibody titer <l:lO. 
7 sera, table 1, and 6 others [MVP6116, MW7851, MYP7852, 
MVP8161, Mvp8166, and LOB] not shown in table 1) were 
challenged with 4 group M viruses including 3 field isolates, 
CA1 (subtype A), CA16 (subtype F), and CI13 (subtype D), 
and a laboratory strain, HIV-IMN (grown in PBMC). None of 
these sera neutralized any of the isolates tested, except for 
MVP7852, which had weak neutralizing antibody titers of 1: 10 
and 1:20 to CA16 and CI13, respectively. To further explore 
these observations, 7 of the 13 HIV-1 group O sera were tested 
€or their capacity to neutralize a wider range of group M iso- 
lates. With rare exceptions, these group O sera failed to neutral- 
ize the group M isolates (table 1). 
Capacity of HIV-1 group M-infected patients ' sei-a to neu- 
tralize €Pups O and M viruses. In contrast to group O sera, 
which had very weak or no neutralizing antibodies to the group 
M viruses, Some group M sera neutralized the group O isolates. 
Of 16 Sera from HIV-1 group M-infected patients, 9 (56.3%) 
had neutralizing antibodies to all 3 HIV-1 group O viruses 
(table 1). At least 1 serum each of subtype B-F and H had 
trophoresis buffer for 3 min at 100°C and electrophoresed on a 
10% SDS-polyacrylamide slab gel, and proteins were transferred to 
nitrocellulose paper. Blotting was done in a Multiphor II Novablot 
(LIU3, Broma,  Sweden) electrophoretic unit for 1 h as described 
P11. 
Results 
Capacity of HIV-1 group O-iilfected patients' sera to neu- 
tralize groups O and M viruses. The ability of group O sera 
to neutralize their autologous contemporaneous (serum col- 
lected at the same time point as virus isolation) or heterologous 
group O viruses was absent or weak (titers ranging from < 1 : 1 O 
to 1:40; table 1). A higher titer was observed for the VI498 
serum to its homologous virus (HIV-lANT70) probably because 
the serum was collected 3.5 years after the virus used in the 
neutralization assay was isolated. 
To determine the presence of neutralizing antibodies in HIV- 
1 group O sera to HIV-1 group M isolates, 13 group O sera (first 
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neutralizing antibodies to group O viruses. However, the 3 
subtype A sera and 2 of subtype G did not neutralize any of 
the HIV-1 group O isolates. 
We hypothesized that HIV-1 group M sera capable of cross- 
neutralizing the very divergent HIV-I group O isolates may 
also neutralize HIV-1 group M field and laboratory isolates 
with even higher titers. To verify this, 7 sera that initially 
neutralized the 3 group O viruses in table 1 were tested for their 
capacity to neutralize 11 field (subtype A-H) and 3 laboratory 
isolates. Six sera that did not neutralize any of the group O 
isolates in table 1 were also included. The 7 sera initially 
neutralizing the group O viruses (table 1) were capable of 
neutralizing a majority of the isolates of subtypes A-H, with 
neutralization titers ranging from 1 : 1 O to > 1 :1280. Among 
the laboratory isolates, H 1 v - l ~ ~  was the most sensitive to 
neutralizing antibodies, with titers ranging from 1:lO to 
>1:1280. The field isolates, CA1 (subtype A) and VI313 (sub- 
type C), were most sensitive, with titers ranging from 1:40 to 
1:640. Two sera, CA5 and CA4, neutralized all isolates (sub- 
type A-H), with titers ranging from 1 :1 O to > 1 :1280. In con- 
trast, 5 of the 6 sera (table 1) that initially did not neutralize 
the HIV-1 group O isolates failed to neutralize the majority of 
the other group M isolates of subtype A-H. With rare excep- 
tions, very weak titers of 1:lO were observed among these 5 
sera. 
No correlation was observed between residual antibody lev- 
els present in the final washing fluid of the neutralization assay 
of sera and their neutralizing titers (data not shown). We inter- 
pret this lack of correlation as a lack of any influence of residual 
antibodies on the neutralizing effect of the sera. 
Correlation between the neutralizing capacity of sera and 
clinical stage. We compared the cross-neutralizing capacity 
to HIV-I group M and group O viruses with disease stages at 
which the sera were obtained. Neutralization of group M or 
group O isolates by homologous or heterologous sera was not 
related to the clinical stage. Sera from asymptomatic (CA5, 
CA20, VI313) and symptomatic (CA4, CA10, CA13, CI22) 
patients had neutralizing antibodies to group M (subtypes A- 
H) and group O viruses (table l). In addition, similar numbers 
of sera lacking neutralizing antibodies to both group M and 
group O viruses were from asymptomatic (CA16, CA18) and 
symptomatic (CA1, VI918, VI526) persons. 
Serum neutralization of virus grown on different host cells. 
Several studies [13, 19, 221 have shown that neutralization 
sensitivity of HIV-1 is due in part to the host cell in which the 
virus is propagated. To verify the effect of the host cells used 
on the neutralizing antibody titers, we prepared stocks of HIV- 
1 ~ ~ ~ 7 0  (a field isolate) and HIV-IIIIB (a laboratory strain) in 
both PBMC and CEMSS cells. These isolates were tested for 
their capacity to become neutralized by 7 broadly cross-neu- 
tralizing and 4 nonneutralizing sera. Overall, the nonneutraliz- 
ing sera did not neutralize both isolates, while the broadly 
cross-neutralizing sera neutralized both isolates in both PBMC 
and CEMSS cell lines (table 2). HIV-1111~ was more sensitive 
to neutralization on CEMSS cells than on PBMC. In particular, 
Table 2. Neutralization of HIV-1ANT70 and HIV-lIIIB on CEMSS 
cell and PBMC assay. 
CEMSS PBMC 
Serum ANT70 IlIB ANT70 IIIB 
CA5 
CI22 
CA10 
CA4 
CA20 
CA13 
VI557 
CA1 
CA18 
CA16 
CA9 
320 
>SO 
40 
320 
10 
20 
10 
- 
- 
- 
- 
1280 
>80 
20 
160 
20 
80 
20 
- 
- 
- 
- 
640 
320 
40 
80 
20 
80 
10 
- 
- 
- 
10 
320 
ND 
10 
40 
10 
20 
10 
- 
- 
- 
- 
NOTE. Neutralization on CEMSS cell line was done essentially as de- 
scribed [ lo]. Data are neutralizing antibody titers expressed as reciprocals. 
PBMC, peripheral blood mononuclear cell; -, titer <1:10. 
3 of 7 broadly cross-neutralizing sera had a 4-fold rise in 
neutralizing antibody titer to HIV-lIIIB on CEMSS cells com- 
pared with neutralization on PBMC. 
Effect of PBMCfrom different donors on infectious HIE 
PBMC from different donors have been shown to vary in their 
susceptibility to HIV infection [23-251. This variation may 
lead to fluctuations in virus titration on different donor PBMC, 
which might subsequently play a role in neutralization. Figure 
2 shows the effect of PBMC from different donors on virus 
titers of some of the isolates during neutralization. A 3-fold 
difference in virus titer on different donor PBMC showed no 
significant effect on the neutralizing antibody titer of sera (fig- 
ure 3). When the virus titer differed by >%fold, in some cases 
there was a significant difference in neutralizing antibody titer. 
In particular, when the titer of virus CI22 dropped 5-fold, the 
neutralizing antibody titer of serum CA9 increased from < 1 : 1 O 
to 1:40 (figure 3A). As a consequence, we considered a neutral- 
ization assay valid if the virus titer (simultaneously titrated on 
the same donor PBMC as used in the neutralization assay) was 
the same or differed by only 3-fold to the initial (input virus) 
titer. 
Sensitivity of ELISA to detect p24 antigen from both group 
M and O virus supernatants. To ensure that our in-house p24 
antigen ELISA could efficiently detect p24 antigen of both 
group M and O viruses, diluted culture supematants with simi- 
lar TCIDSO of 2 group M (CAI and CA131 and 3 group O 
(HIV-1 ANTTO, VI686, and CA9) viruses were tested and optical 
densities were compared. Detection of p24 in both group M 
and O diluted culture supernatants were similar, as indicated 
by optical densities (figure 4). These results indicate that our 
in-house p24 antigen-capture ELISA detects p24 in group M 
and O virus supernatants with a similar sensitivity. 
Relationship between the neutralization ability of antibodies 
and binding capacity on V3 loop peptides and Western blot. 
The relationship between the V3 loop peptide-binding capacity 
D 
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Figure 2. Effect of different donor peripheral blood 
mononuclear cells on HIV- 1 titers: O on x axis, reference 
virus titer. 
of sera and ìheir functional activity as measured in a neutraliza- 
tion assay was determined for homologous and heterologous 
isolates. In most cases, high V3 loop peptide-binding capacity 
of sera did not reflect their capacity to neutralize the homolo- 
gous isolate (figure 5). In particular, of 10 sera with high reac- 
tivity to the peptide of HIV-IMN, only 4 neutralized the homolo- 
gous isolate, with a neutralizing antibody titer of z= 1 :320, while 
5 lacked neutralizing antibodies (titer s 1: IO). Of more interest, 
of 9 group M sera that lacked reactivity for HIV-~ANT~O V3 
loop peptide, 6 neutralized the homologous (HIV-~AN~O) virus, 
with titers ranging from 1:20 to 1:640. Conversely, 2 group O 
sera, CA9 and VI686, which were highly reactive with HIV- 
1ANT70 V3 loop peptide, had very weak (titer, 1:lO) or no neu- 
tralizing antibody to HIV-IANT70. However, reactivity of 2 sub- 
type B sera with H N - l m  but not HIV-IIIIB V3 peptide and 1 
group O serum (VI498) with HIV-lANT70 V3 peptide correlated 
with neutralization of the homologous isolate (figure 5). These 
data demonstrate the lack of correlation between neutralizing 
activity and reactivity to V3 loop peptide in ELISA. 
When we compared the reactivity of group M sera to HIV- 
1ANT70 gp41 on Western blot with the presence of neutralizing 
antibodies to H N -  1ANT70, only 4 of 8 sera that neutralized HIV- 
1A~T70 reacted with gp41 on Western blot. Three of 5 sera that 
lacked neutralizing antibodies to H N - ~ A N T ~ o  also reacted with 
gp41 on Western blot. None of the group M sera reacted with 
H 1 v - 1 ~ ~ ~ 7 0  gp120, irrespective of their neutralizing capacity, 
whereas the group O sera did. 
Discussion 
A successll vaccine against HIV-I must elicit an immune 
response that protects against infection by numerous genetic 
variants that characterize this virus. To our knowledge, this is 
the first study in which genetically characterized primary HIV- 
1 group M isolates, representing 8 different genetic subtypes, 
and HIV-1 group O isolates have been used in a PBMC-based 
neutralization assay, with homologous and heterologous poly- 
clonal sera. 
A significantly higher number of sera (9/16) from patients 
infected with different genetic subtypes of group M neutralized 
the 3 HIV-1 group O isolates than did group O sera (3/13) 
which only sporadically had weak neutralizing antibodies (titer, 
1:lO-1:20) to 5 of 18 HIV-1 group M viruses of 8 different 
genetic subtypes. This inability of sera of HIV-1 group 0- 
infected persons to cross-neutralize HIV-1 group M viruses 
could be attributed first to the genetic diversity (50%) in the 
env gene product that distinguishes both groups [7]. Second, 
antibodies induced by HIV-1 group O viruses perhaps fail to 
recognize the equivalent HIV-I group M antigens or the coun- 
terpart group M antigens may not be accessible to HIV-1 group 
O antibodies because of differences in glycosylation patterns 
that might mask the epitopes [26]. Last, it is possible that HIV- 
1 group O viruses lack strong immunogenic epitopes necessary 
to initiate production of neutralizing antibodies to group M 
viruses. This possibility is in line with the weak cross-neutral- 
ization observed within the group O viruses compared with the 
group M viruses. However, the number of group O sera and 
isolates analyzed may be too limited for a final conclusion. 
Of interest, the HIV-1 group M-infected sera neutralized 
all of the group O isolates with a conspicuous similarity in 
titer. Furthermore, these group M sera consistently neutralized 
other group M isolates of diverse genetic subtypes. The possi- 
bility exists that sera of some HIV-1 -infected persons contain 
mixtures of antibodies induced at different moments after infec- 
tion against different HIV-I isolates. Consequently, broadly 
cross-neutralizing sera may contain a population of antibodies 
directed against a single or multiple conserved epitopes present 
in all 8 subtypes of HIV-I group M and in group O viruses. 
Our results clearly demonstrate that the ability of sera to 
neutralize isolates or for isolates to be neutralized by sera did 
not cxm~late with the genetic subtype. These results do not 
confirm the findings of Mascola et al. [ 141, who used primary 
HIV-1 isolates representing 2 distinct genetic subtypes (B and 
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Figure 3. Effect of different do- 
nor peripheral blood mononuclear 
cells on HIV-I titers and neutralizing 
antibody titers of sera: O on x axis, 
reference (input) virus titer; NA, 
neutralizing antibody. Drop (>3- 
fold, A) and increase (C) in titer re- 
sults in corresponding increase and 
decrease, respectively, in NA titer. 
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Figure 4. Sensitivity of HIV-1 p24 antigen-capture ELISA to detect p24 antigen in culture supernatants of HIV-1 group M and O viruses. 
OD, optical density. Note similarity in ODs for both groups. 
E) to demonstrate that they represent distinct neutralization 
serotypes. Similar to our findings, studies by others using 
monoclonal antibodies mostly directed against CD4 conforma- 
tional epitopes [13, 271 or anti-HIV-l-positive human sera 
[ 1 O, 281 demonstrated broad cross-neutralizing antibodies to 
distinct genetic subtypes of HIV-I group M or group O viruses 
(or both). In particular, serum CA5 (subtype B) and CA4 (sub- 
type F; table 1) neutralized all isolates of group M and group 
O tested. Taken together, these results indicate that the consid- 
erable genetic diversity observed within HIV-1 isolates does 
not reflect a similar diversity in neutralization serotypes. Fur- 
thermore, the cross-neutralizing capacity of sera was not related 
to the clinical stage of disease, since similar numbers of asymp- 
tomatic and symptomatic patients' sera had equivalent capacity. 
Thus far, HN-1 isolates have been phylogenetically classi- 
fied into different subtypes on the basis of sequence informa- 
tion. The data in table l suggest that both sera and HIV-l 
isolates can also be grouped by the homology of their neutral- 
ization spectrum (serotype). Each row in table 1 can be re- 
garded as a serum neutralization spectrum and each column as 
an isolate neutralization spectrum. The serum neutralization 
spectrum of HIV-1 group O-infected persons was remarkably 
different from HIV-1 group M-infected persons. In particular, 
the neutralization spectra of CA5 and CA4 look similar, in that 
both sera were capable of neutralizing (with high neutralizing 
antibody titers) all isolates (table 1) representing HIV-1 group 
O and 8 different genetic subtypes of group M. Conversely, a 
close homology in the neutralization spectra of group O sera 
was observed, whereby most of them failed to neutralize the 
group M isolates. Therefore, the possibility exists that if sera 
and HIV-1 isolates are classified into neutralization serotypes, 
conserved epitopes involved in neutralization may be identified 
in some key isolates in each group. 
Although this study was not designed to address the issue 
of reproducibility of neutralization assays, two observations 
are of note. First, neutralization sensitivity of HIV has been 
reported to be due in part to the cell in which the virus is 
propagated [13, 191. The neutralizing antibody titers of sera to 
HIV-lANT70 and HIV-lIIIB on PBMC and CEMSS cells were 
comparable, even though not reproducible; however, neutral- 
ization of HIV-lIIIB was relatively higher on CEMSS cells 
than on PBMC. Second, there has been considerable concern 
regarding the validity of PBMC-based neutralization assays 
with primary viruses [29, 301. In particular, it is wise to note 
that variation in PBMC infectability of different donors will 
certainly have implications in neutralization assays. However, 
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Figure 5. Relationship between neutralizing and V3 loop peptide-binding antibodies in sera of persons infected with HIV-I group M 
(subtypes shown in parentheses) and O viruses: ND, not done; OD V3, optical density of V3 loop peptide ELISA. OD of 0.5 was considered 
positive; <OS, negative. 
in a recent study addressing the issue of PBMC infectability 
by primary HIV-1 isolates, Spira and Ho [24] demonstrated a 
40-fold range of infection of different donor PBMC, which is 
less than the 1000-fold previously reported by others [23, 251, 
and that no donor cells totally resisted infection. In our study, 
the acceptable variation range of virus titer considered valid 
for a neutralization assay was a 3-fold difference. We observed 
that neutralizing antibody titers of sera were similar as long as 
the variation in titer was within the acceptable range of 3-fold 
difference. These results indicate that using different donor 
PBMC with less variation of infectivity by primary HIV-1 for 
neutralization assays yields valid results. 
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Several determinants of the HIV-1 envelope have previously 
been suggested to be involved in virus neutralization [31-381. 
Most of these studies have focused on the third variable region 
(V3) of gp120, and because of its importance as the principal 
neutralization epitope, it has become a favored target for serol- 
ogy aimed at characterizing virus isolates. Reactivity with pep- 
tides was compared with the presence of neutralizing antibodies 
to the honifilogous isolates. With rare exceptions, reactivity 
with V3 peptide did not correlate with neutralization of the 
homologous isolate (figure 5) nor with HIV-1ANT70 gp41 on 
Western blot. These results provide indirect evidence that the 
cross-neutralizing activity of human sera may be due in part 
to antibodies directed to conformational epitopes in HIV-I 
a120 or gp41. Mapping of such conserved cross-neutralizing 
epitopes is invaluable for the development of a polyvalent HIV 
vaccine. 
In conclusion, these results demonstrate that despite the re- 
duced capacity of sera of HIV-I group O-infected persons to 
neutralize group M viruses, both HIV-I group M (subtype A- 
H) and group O viruses are sensitive to neutralization by anti- 
HIV-1 group M-positive sera from patients infected with dif- 
ferent genetic subtypes. A method to classify sera and HIV-I 
isolates of diverse genetic subtypes by the homology of their 
neutralization spectra is therefore needed, which may lead to 
the identification and characterization of some key epitopes 
present in a large set of genetically diverse HIV-I isolates that, 
in a suitable vaccine preparation, can help to induce protective 
immunity in a naive person. Studies similar to ours; aimed at 
determining the antigenic relationship of HIV-2 and simian 
immunodeficiency virus, are invaluable. 
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